Literature DB >> 17319131

Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx).

Alexander Cole1, Adrian Mutlow, Ramiro Isaza, James W Carpenter, David E Koch, Robert P Hunter, Betsy L Dresser.   

Abstract

The pharmacokinetic parameters of carfentanil and naltrexone were determined in the common eland (Taurotragus oryx). Six adult females were immobilized with xylazine (0.23 +/- 0.03 mg/kg i.m.) and carfentanil (0.0169 +/- 0.0005 mg/kg i.m.) for a 45-min period, during which time routine health care procedures were performed. Heart and respiration rates and body temperatures were monitored throughout the immobilization period. A single intramuscular injection of naltrexone (1.66 +/- 0.08 mg/kg i.m.) was sufficient for reversal. The eland were intermittently restrained in a hydraulic squeeze chute for serial blood sample collection via jugular venipuncture during immobilization and up to 48 hr post-immobilization. The quantification of carfentanil and naltrexone in the plasma was performed by liquid chromatography and mass spectroscopy methods. Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C(max)) at 13.8 min. Naltrexone was readily absorbed and reached C(max) at 23.4 +/- 16.8 min after administration. All animals stood 2.7 +/- 2.2 min after naltrexone administration. Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr. Although respiratory rates appeared to fluctuate widely among animals, heart rates and body temperature remained stable throughout the immobilization. Renarcotization was not noted as a major complication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17319131     DOI: 10.1638/05-070.1

Source DB:  PubMed          Journal:  J Zoo Wildl Med        ISSN: 1042-7260            Impact factor:   0.776


  4 in total

1.  Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Neuropharmacology       Date:  2019-04-06       Impact factor: 5.250

2.  Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Authors:  Michael G Feasel; Ariane Wohlfarth; John M Nilles; Shaokun Pang; Robert L Kristovich; Marilyn A Huestis
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

3.  Synthesis and μ-Opioid Activity of the Primary Metabolites of Carfentanil.

Authors:  Fu-Lian Hsu; Andrew J Walz; James M Myslinski; Li Kong; Michael G Feasel; Tyler D P Goralski; Tim Rose; Nicholas J Cooper; Neil Roughley; Christopher M Timperley
Journal:  ACS Med Chem Lett       Date:  2019-10-16       Impact factor: 4.345

Review 4.  Metabolic clearance of select opioids and opioid antagonists using hepatic spheroids and recombinant cytochrome P450 enzymes.

Authors:  Wing Y Tuet; Samuel A Pierce; Matthieu Conroy; Justin N Vignola; Justin Tressler; Robert C diTargiani; Bryan J McCranor; Benjamin Wong
Journal:  Pharmacol Res Perspect       Date:  2022-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.